Polymorphic markers of the LSR gene

An isolated, purified, or recombinant polynucleotide which encodes a polypeptide comprising a contiguous span of at least 6 amino acids of any one of SEQ ID Nos:

• 14, 16, and 18, wherein said contiguous span includes any one of the following:
• a serine residue at position 363 of SEQ ID NO:
• 14;
• an asparagine residue at position 363 of SEQ ID NO:
• 14;
• a proline residue at position 420 of SEQ ID NO:
• 14;
• an arginine residue at position 420 of SEQ ID NO:
• 14;
• an arginine residue at position 519 of SEQ ID NO:
• 14;
• a one amino acid deletion at position 519 of SEQ ID NO:
• 14;
• a serine residue at position 344 of SEQ ID NO:
• 16;
• an asparagine residue at position 344 of SEQ ID NO:
• 16;
• a proline residue at position 401 of SEQ ID NO:
• 16;
• an arginine residue at position 401 of SEQ ID NO:
• 16;
• an arginine residue at position 500 of SEQ ID NO:
• 16;
• a one amino acid deletion at position 500 of SEQ ID NO:
• 16;
• a serine residue at position 295 of SEQ ID NO:
• 18;
• an asparagine residue at position 295 of SEQ ID NO:
• 18;
• a proline residue at position 352 of SEQ ID NO:
• 18;
• an arginine residue at position 352 of SEQ ID NO:
• 18;
• an arginine residue at position 451 of SEQ ID NO:
• 18;
• and a one amino acid deletion at position 451 of SEQ ID NO:
• 18.

A method of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising:

• a) genotyping at least one LSR-related biallelic marker according to claim 30 for each individual in said population;
• b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population;
• and
• c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency.

An isolated, purified, or recombinant polypeptide comprising a contiguous span of at least 6 amino acids of any one of SEQ ID Nos:

• 14, 16, and 18, wherein said contiguous span includes any one of the following:
• a serine residue at position 363 of SEQ ID NO:
• 14;
• an asparagine residue at position 363 of SEQ ID NO:
• 14;
• a proline residue at position 420 of SEQ ID NO:
• 14;
• an arginine residue at position 420 of SEQ ID NO:
• 14;
• an arginine residue at position 519 of SEQ ID NO:
• 14;
• a one amino acid deletion at position 519 of SEQ ID NO:
• 14;
• a serine residue at position 344 of SEQ ID NO:
• 16;
• an asparagine residue at position 344 of SEQ ID NO:
• 16;
• a proline residue at position 401 of SEQ ID NO:
• 16;
• an arginine residue at position 401 of SEQ ID NO:
• 16;
• an arginine residue at position 500 of SEQ ID NO:
• 16;
• a one amino acid deletion at position 500 of SEQ ID NO:
• 16;
• a serine residue at position 295 of SEQ ID NO:
• 18;
• and asparagine residue at position 295 of SEQ ID NO:
• 18;
• a proline residue at position 352 of SEQ ID NO:
• 18;
• an arginine residue at position 352 of SEQ ID NO:
• 18;
• an arginine residue at position 451 of SEQ ID NO:
• 18;
• and a one amino acid deletion at position 451 of SEQ ID NO:
• 18.

A method of using a drug, comprising:

• obtaining a nucleic acid sample from an individual;
• determining the identity of the polymorphic base of one or more LSR biallelic markers in said nucleic acid sample;
• and
• administering said drug to said individual if said polymorphic base of said one or more LSR biallelic markers is associated with a positive response to treatment with said drug or is not associated with a negative response to treatment with said drug.

A method of screening an individual for inclusion in a clinical trial of a drug comprising:

• obtaining a nucleic acid sample from said individual;
• determining the identity of the polymorphic base of one or more LSR biallelic markers in said nucleic acid sample;
• and
• including said individual in said clinical trial if said polymorphic base of said one or more LSR biallelic markers is associated with a positive response to treatment with said drug or is not associated with a negative response to treatment with said drug.